TIA & secondary stroke prevention: the AU general practice framework

A transient ischaemic attack (TIA) is a focal neurological deficit — weakness, speech difficulty, facial droop, visual loss — that resolves fully, without imaging-proven brain infarction. The modern definition is clinical-imaging: resolution of symptoms plus no infarction on diffusion-weighted MRI. What TIA is not is a “warning you got away with.” It is a stroke emergency with a 10–20% risk of recurrent stroke within 90 days, and approximately half that risk is compressed into the first 48 hours.

The Stroke Foundation of Australia Clinical Guidelines for Stroke Management (2022 living guideline) are unambiguous: all suspected TIA or minor stroke requires same-day or urgent (within 24 hours) specialist assessment. The old ABCD² risk-score approach — which allowed lower-scoring TIA to be seen routinely — is no longer supported by evidence or guideline. Time to assessment is determinant of outcome.

The GP role in TIA spans acute recognition and immediate escalation, post-event management of the secondary prevention bundle, long-term cardiovascular risk reduction, and coordination of multidisciplinary rehabilitation when needed.

A. Core clinical — the AU general practice framework

Acute recognition

The FAST mnemonic — Face droop, Arm weakness, Speech difficulty, Time (call 000) — remains the primary community-facing tool for stroke recognition. The extended BE FAST adds Balance loss and Eyes (sudden vision change, diplopia). Any patient presenting to general practice with these features acutely requires 000 and hospital, not clinic assessment and same-day follow-up.

TIA more often presents retrospectively — the patient had a spell yesterday, is back to normal today, and has come in wondering what happened. The history should establish:

• Territorial pattern — anterior circulation (MCA/ACA: face, hand, arm, speech, visual field loss) versus posterior circulation (vertebrobasilar: diplopia, dysarthria, dysphagia, ataxia, bilateral limb involvement, sudden vision loss, severe vertigo).
• Onset and duration — abrupt onset and rapid resolution to baseline is characteristic. Gradual onset, march of symptoms, or positive symptoms (spreading tingling, spreading weakness) raise the differential of migraine aura or focal seizure.
• Duration — minutes is typical for TIA; days-long resolution suggests completed stroke or Todd’s paresis.
• Associated features — headache raises haemorrhagic concern; chest pain or palpitations suggest cardioembolic source; positional or postural precipitation raises vertebrobasilar stenosis.
• Vascular risk factor history — hypertension, type 2 diabetes, hypercholesterolaemia, atrial fibrillation, smoking, prior TIA or stroke, peripheral arterial disease.

Workup

The workup is urgent — requested on the day, not scheduled for next week:

• Non-contrast CT head — excludes haemorrhagic stroke; widely accessible; does not diagnose TIA (MRI needed for that).
• MRI brain with DWI sequence — confirms or refutes ischaemic infarction; recommended within 72 hours.
• 12-lead ECG — detects AF, conduction abnormalities, LVH.
• Carotid imaging — Doppler ultrasound, CTA, or MRA to quantify stenosis; mandatory for intervention planning (threshold is 70–99% symptomatic stenosis for endarterectomy).
• 48-hour Holter monitoring or longer event monitor — paroxysmal AF is detected in a proportion of patients with TIA who have sinus rhythm on initial ECG; its detection completely changes management to anticoagulation.
• Implantable loop recorder (ILR) — for cryptogenic TIA/stroke where shorter monitoring is negative; the CRYSTAL-AF trial showed ILR detected AF in 12.4% at three years versus 2% with conventional monitoring.
• Echocardiogram (TTE first; TOE if cardioembolic source or PFO suspected) — cardiac thrombus, atrial size, valvular disease.
• Bloods — FBE, electrolytes, fasting lipids, fasting glucose and HbA1c, INR/coagulation; ESR and CRP if vasculitis considered; thrombophilia screen (antiphospholipid antibodies, protein C/S, Factor V Leiden) in younger patients with cryptogenic TIA.

Acute antithrombotic strategy

Per Stroke Foundation 2022, for high-risk TIA (ABCD² ≥4) or minor ischaemic stroke (NIHSS ≤3) without thrombolysis: 21-day dual antiplatelet therapy (DAPT) started within 24 hours.

The regimen is aspirin 300 mg loading dose then 100 mg daily plus clopidogrel 300 mg loading dose then 75 mg daily for 21 days, followed by long-term antiplatelet monotherapy (clopidogrel 75 mg daily preferred, or aspirin 100 mg daily).

For lower-risk TIA: aspirin 100 mg daily or clopidogrel 75 mg daily monotherapy long-term.

For AF-related TIA: anticoagulation per CHA₂DS₂-VA — DOAC preferred; timing guided by infarct size (see Section E).

B. Evidence appraisal — DAPT, statins, and blood pressure

21-day dual antiplatelet therapy

The CHANCE trial (Wang et al., NEJM 2013) enrolled 5,170 Chinese patients with high-risk TIA or minor stroke within 24 hours. Aspirin plus clopidogrel (21 days) versus aspirin alone reduced 90-day stroke by 32% (8.2% versus 11.7%), with no significant increase in major haemorrhage. The POINT trial (Johnston et al., NEJM 2018) confirmed this in 4,881 Western patients: 90-day composite of stroke, MI, or death reduced by 25% (5.0% versus 6.5%), with a modest increase in major haemorrhage at extended follow-up — reinforcing the 21-day limit.

Long-term dual antiplatelet is harmful: the MATCH trial demonstrated no additional stroke reduction and significantly increased major haemorrhage with prolonged dual therapy beyond the acute phase.

High-intensity statin therapy

The SPARCL trial (Amarenco et al., NEJM 2006) enrolled 4,731 patients with recent stroke or TIA: atorvastatin 80 mg versus placebo reduced recurrent stroke by 16% at five years (11.2% versus 13.1%). Post-stroke LDL-C target is below 1.8 mmol/L per Stroke Foundation 2022; some international guidelines advocate below 1.4 mmol/L in very-high-risk individuals. First-line: atorvastatin 40–80 mg or rosuvastatin 20–40 mg. Ezetimibe is added if LDL-C target is not met on maximum statin. PCSK9 inhibitors (alirocumab, evolocumab) carry PBS Authority requirements for very-high-risk patients failing maximum statin plus ezetimibe.

Blood pressure reduction

The PROGRESS trial (Lancet 2001) enrolled 6,105 patients with prior stroke or TIA: perindopril plus indapamide reduced recurrent stroke by 43% (10% versus 14% at four years). The Heart Foundation 2023 guideline targets below 130/80 mmHg. The ACE inhibitor / ARB plus thiazide combination is the preferred regimen. Blood pressure should not be lowered aggressively in the first 24–72 hours post-stroke — the ischaemic penumbra depends on autoregulatory perfusion pressure, and acute lowering worsens outcomes.

Carotid endarterectomy

For symptomatic internal carotid stenosis 70–99%, carotid endarterectomy (CEA) within two weeks of TIA or minor stroke reduces 2-year absolute stroke risk by ~16% (NASCET and ECST trials). Benefit falls substantially if surgery is delayed beyond two weeks. For 50–69% symptomatic stenosis, benefit is smaller and selective. Carotid artery stenting is an alternative for patients at high surgical risk (CREST trial). Asymptomatic carotid stenosis >70% carries a much smaller benefit with modern medical therapy approaching equipoise; vascular surgery specialist assessment guides individual decisions.

C. Secondary prevention bundle — the eight-element strategy

Approximately 25% of all strokes are recurrent events. Intensive secondary prevention implemented across all modifiable risk factors reduces recurrence by up to 80% (Stroke Foundation 2022). No single element is sufficient; the cumulative benefit requires the full bundle.

1. Antithrombotic — antiplatelet monotherapy long-term for atherothrombotic TIA; DOAC for AF-related.

2. Blood pressure — target below 130/80 mmHg; ACE inhibitor or ARB plus thiazide diuretic (PROGRESS regimen). Initiate or intensify after the acute stabilisation period.

3. Lipid lowering — high-intensity statin; LDL-C below 1.8 mmol/L; ezetimibe add-on if needed.

4. Smoking cessation — the single most impactful modifiable factor; an estimated 50% reduction in recurrence risk. Nicotine replacement therapy (PBS-listed), varenicline (PBS Authority), or bupropion (PBS Authority) are first-line pharmacotherapy.

5. Physical activity — at least 150 minutes of moderate aerobic activity per week; two sessions per week of resistance training.

6. Diet — Mediterranean pattern (olive oil, vegetables, legumes, nuts, fish); reduced sodium for hypertension management. The PREDIMED trial supports Mediterranean diet for primary cardiovascular prevention; secondary prevention extrapolation is guideline-supported.

7. Glucose and metabolic — HbA1c individualised (typically below 7%) in type 2 diabetes; SGLT2 inhibitor (empagliflozin, dapagliflozin) preferred for T2DM with established cardiovascular disease — PBS Authority-listed for T2DM plus CV or CKD criteria; GLP-1 receptor agonists (semaglutide, dulaglutide) similarly PBS Authority-listed for T2DM with established CV disease.

8. Obstructive sleep apnoea (OSA) — independent stroke risk factor; STOP-BANG screening at every visit; CPAP for AHI ≥15 or symptomatic OSA. OSA treatment improves nocturnal blood pressure and cardiovascular risk profile.

PFO closure — for cryptogenic stroke in patients under 60 years with high-risk PFO features (large PFO size, atrial septal aneurysm, right-to-left shunt demonstrated on bubble study): the CLOSE, RESPECT-Extended, and REDUCE trials support closure; cardiology evaluation and heart team decision.

D. Australian operations

MBS items

Standard general practice consultations (MBS Online): items 23, 36, 44. The GP Chronic Condition Management Plan (GPCCMP — items 965 and 967), which replaced items 721/723/732 from 1 July 2025, enables chronic disease management coordination and access to five or more allied health sessions per year for post-TIA rehabilitation. The 75+ Health Assessment (item 707) and the Aboriginal and Torres Strait Islander Health Assessment (item 715) both include cardiovascular risk review. Post-stroke depression and anxiety are supported under the Better Access Mental Health Care Plan (item 2715), up to 10 sessions per year with a psychologist.

Key investigation MBS items: carotid Doppler (item 55244); brain MRI (item 63007); CTA head and neck (item range 56301+); TTE and TOE are Medicare-rebatable through cardiology referral.

PBS medications

• Aspirin 100 mg — OTC and PBS general.
• Clopidogrel 75 mg — PBS general.
• DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) — PBS Authority Required for non-valvular AF stroke prevention.
• Atorvastatin, rosuvastatin (high-intensity statins) — PBS general.
• Ezetimibe — PBS general; combination product Atozet available.
• PCSK9 inhibitors (alirocumab, evolocumab) — PBS Authority Required for very-high-risk patients failing maximum statin plus ezetimibe above LDL-C threshold.
• SGLT2 inhibitors and GLP-1 receptor agonists — PBS Authority for T2DM with established CV, heart failure, or CKD criteria.
• Smoking cessation — nicotine replacement therapy on PBS general prescribing pathway; varenicline and bupropion on PBS Authority.

Driving — Austroads 2022

Private vehicle licence holders: not to drive for four weeks after non-disabling TIA or minor stroke. Commercial vehicle holders: advised to cease for three months. Specific cognitive, visual field, and motor criteria apply; on-road driving assessment may be required. Documenting the driving advice given is a medicolegal requirement — the patient also needs to be advised to inform their state licensing authority.

Stroke services in Australia

The Stroke Foundation maintains a directory of Primary Stroke Units and Comprehensive Stroke Centres across Australia. Telestroke services provide regional and rural access to tertiary stroke neurologists. Rapid-access TIA clinics operate in metropolitan and increasing numbers of regional centres.

E. Special populations

Older adults (≥75 years). The full secondary prevention bundle applies but polypharmacy, frailty, and falls risk warrant individual assessment. The absolute benefit of blood pressure reduction is maintained, though specific targets may be adjusted with specialist input. DOAC dose reduction criteria apply for older adults with renal impairment, low body weight, or age ≥80 — apixaban 2.5 mg twice daily if two of: age ≥80, weight ≤60 kg, creatinine ≥133 µmol/L. Falls risk from anticoagulation is significant but usually does not outweigh the stroke prevention benefit; a structured frailty assessment assists.

Younger adults and cryptogenic TIA/stroke (under 60 years). This group requires extended AF monitoring — paroxysmal AF is detected by ILR in up to 12% at three years (CRYSTAL-AF) and changes management completely. PFO evaluation is important: the CLOSE, RESPECT-Extended, and REDUCE trials support PFO closure for cryptogenic stroke under 60 with high-risk features. Hypercoagulable workup (antiphospholipid syndrome, Factor V Leiden, protein C/S, ATIII deficiency) is warranted in atypical presentations or family history.

Anticoagulation timing in AF-related stroke. The clinical ‘1-3-6-12 day’ rule guides DOAC initiation: 1 day after TIA, 3 days after minor infarct, 6 days after moderate, 12 days after large infarct — balancing re-embolism against haemorrhagic transformation risk. This requires specialist input.

Migraine with aura. The combined oral contraceptive pill (COC) is contraindicated in women with migraine with aura, per RACGP and WHO Medical Eligibility Criteria — the combination significantly elevates ischaemic stroke risk.

Aboriginal and Torres Strait Islander peoples. Stroke incidence is higher and age of first presentation younger. The ATSI Health Assessment (item 715) includes cardiovascular risk review. Culturally safe care through ATSI community-controlled health organisations and the Heart Foundation’s ATSI cardiovascular health program supports this population.

When to escalate

• All suspected TIA or minor stroke — same-day specialist neurology or stroke unit assessment; do not defer.
• Haemodynamic instability, wide-complex tachycardia, or severe headache — emergency (000).
• Symptomatic carotid stenosis 70–99% — urgent vascular surgery referral; maximum benefit from CEA within two weeks.
• Cryptogenic TIA under 60 years — cardiology for PFO assessment; prolonged AF monitoring with ILR.
• AF detected post-TIA — anticoagulation initiation with specialist timing guidance.
• Recurrent TIA on treatment — urgent specialist review; medication optimisation or further workup.
• Post-stroke depression, anxiety, or cognitive impairment — psychology or neuropsychology; Better Access Mental Health Care Plan; SSRI if indicated.

What this article is and is not

This is general health information drawn from current Australian guidelines — Stroke Foundation of Australia Clinical Guidelines for Stroke Management (2022 living guideline), Heart Foundation 2023, Therapeutic Guidelines, Australian Medicines Handbook — and key clinical trial evidence including the CHANCE, POINT, SPARCL, and PROGRESS trials. It is not personal medical advice and does not create a doctor–patient relationship. Every TIA is different; treatment decisions — including which antithrombotic regimen, whether carotid endarterectomy is indicated, timing of anticoagulation, and individual risk factor targets — are made by your own GP and treating specialists based on your complete clinical picture.

For Australian consumer resources: HealthDirect — TIA, Better Health Channel — Stroke, Stroke Foundation Australia.

For acute stroke or TIA: call 000 immediately.

---

Sources cited

1. Stroke Foundation Australia — Clinical Guidelines for Stroke Management (2022 living guideline)
2. Heart Foundation — Australian guideline for CV risk (2023)
3. Therapeutic Guidelines (eTG) — Cardiovascular / Neurology
4. Australian Medicines Handbook (AMH)
5. RACGP
6. PBS
7. MBS Online
8. Austroads — Assessing Fitness to Drive 2022
9. Wang Y et al. — CHANCE trial (NEJM 2013)
10. Johnston SC et al. — POINT trial (NEJM 2018)
11. Amarenco P et al. — SPARCL trial (NEJM 2006)
12. PROGRESS Collaborative Group — perindopril/indapamide after stroke (Lancet 2001)
13. HealthDirect — TIA
14. Better Health Channel — Stroke